导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -23.62% | 4491/4773 |
| 近一周 | -5.03% | 5214/5462 |
| 近一月 | -7.23% | 3760/5421 |
| 近一季 | -3.90% | 1494/5209 |
| 近半年 | -19.99% | 4367/4920 |
| 近一年 | -33.85% | 4279/4366 |
| 近两年 | -16.35% | 2950/2954 |
| 近三年 | -49.06% | 2249/2253 |
| 成立以来 | 39.76% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-8.21% 4263/4961 |
-20.28% 4873/5312 |
- - |
- - |
| 2025 | -12.96% 3399/4813 |
-0.21% 2106/3635 |
-9.63% 3618/4076 |
6.18% 3546/4524 |
-9.09% 4007/4813 |
| 2024 | -11.10% 2351/3463 |
-0.30% 1096/2808 |
-14.58% 2671/3014 |
16.78% 1350/3129 |
-10.61% 2996/3463 |
| 2023 | -18.70% 1824/2656 |
7.97% 508/2280 |
-17.13% 2259/2385 |
2.02% 261/2515 |
-10.93% 2390/2655 |
| 2022 | -10.98% 225/2207 |
-22.98% 1720/1919 |
26.53% 5/2016 |
-11.60% 550/2113 |
3.32% 721/2208 |
| 2021 | -2.60% 861/1822 |
-11.42% 1134/1255 |
19.68% 157/1330 |
-13.49% 1344/1466 |
6.20% 228/1822 |
| 2020 | 125.32% 8/1250 |
-9.70% 711/1028 |
39.41% 6/1067 |
21.68% 40/1164 |
47.10% 8/1184 |
| 2019 | - - |
- - |
- - |
4.93% 174/850 |
6.58% 590/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 鹏华中证酒ETF VS. 长安沪深300非周期A(740101) |